Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Biotechnology

Healthcare
$2.82 -1.97%

-$0.24 today

Market cap
$54.80M
Beta
1.68
P/E (TTM)
-1.1
EPS (TTM)
-$10.75
52W Low $10.03High $69.97

Volume 1.04M

Average 0.49M

TNXP Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Tonix Pharmaceuticals Holding Corp.NASDAQ: TNXP

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $2.13M rose 126.2% year over year, ahead of the +18.0% change in trailing-twelve-month cost of revenue. Sequentially, it rose 38.0% from the prior quarter.

Context

  • Cost of revenue amounted to 65.3% of revenue in FY2025, down 11.6 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +126.2% holds above the trailing-twelve-month pace of +18.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.13M+38.0% QoQ
Last fiscal yearDec 2025
$8.57M+10.3% YoY
LTMMar 2026
$8.32M+18.0% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+126.2%——
1 year+10.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
8.57M USD
Year-over-year change
+10.3%

Cost of Revenue vs competitors

How TNXP compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +18.0% is the 2nd highest of 7, against a peer median of -80.6%.
  • Cost of revenue amounts to 47.4% of revenue for TNXP, versus a peer median of 120.9%.
TNXP Competitors
Cost of Revenue for TNXP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$32.58M USD-62.0%-2.1%515.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$10.68M USD+89.7%—18096.6%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$8.32M USD+18.0%—47.4%
NKTXNkarta, Inc.LTM Mar 2026$2.34M USD———
MCRBSeres Therapeutics, Inc.LTM Mar 2026$1.39M USD-86.2%—120.9%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$289K USD-75.2%+2.2%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$95K USD——5.3%
FBRXForte Biosciences, Inc.LTM Mar 2026$6K USD-86.0%——
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
IPHAInnate Pharma S.A.FY2025€0 EUR-100.0%—0.0%
Peer median (excluding TNXP) —-80.6%+0.0%120.9%

Competitors are the stored peer set for TNXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue007.77M10.09M13.11M
Cost of Revenue004.74M7.77M8.57M
Gross Profit003.03M2.33M4.54M
Gross Margin——39.0%23.1%34.7%
Research & Development68.84M81.88M86.66M40.45M44.49M
Selling, General & Admin23.47M30.22M34.75M40.1M85.76M
Operating Expenses92.31M112.09M121.41M139.03M130.25M
Depreciation & Amortization50K1.25M4.29M3.42M1.93M
EBITDA(92.24M)(108.97M)(112.37M)(74.32M)(122.01M)
EBITDA Margin——-1446.5%-736.3%-930.9%
Operating Income(92.31M)(112.09M)(118.38M)(136.7M)(125.7M)
Operating Margin——-1523.9%-1354.3%-959.1%
Interest Income25K1.87M004.15M
Interest Expense000089K
Other Income / Expenses25K1.87M1.72M6.67M1.68M
Income Before Tax(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Pre-Tax Margin——-1501.8%-1288.3%-946.2%
Income Tax Expense00000
Net Income(92.29M)(110.22M)(116.66M)(130.04M)(124.02M)
Net Margin——-1501.8%-1288.3%-946.2%
EPS (Basic)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
EPS (Diluted)(163,968.00)(811.68)(6,368.84)(176.60)(14.57)
Weighted Avg Shares5633.07M1.83M2.26M8.51M
Weighted Avg Shares (Diluted)5633.07M1.83M2.26M8.51M

Tonix Pharmaceuticals Holding Corp.

NASDAQ:TNXP

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.